Long-Term Efficacy and Safety of Golimumab for Ulcerative Colitis in a Pediatric Inflammatory Bowel Disease Center in Japan

PURPOSE: Golimumab (GLM) is an anti-tumor necrosis factor (TNF)-α antibody preparation known to be less immunogenic than infliximab (IFX) or adalimumab. Few reports on GLM in pediatric patients with ulcerative colitis (UC) are available. This study aimed to review the long-term durability and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokita, Kazuhide, Shimizu, Hirotaka, Takeuchi, Ichiro, Shimizu, Toshiaki, Arai, Katsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679302/
https://www.ncbi.nlm.nih.gov/pubmed/36451693
http://dx.doi.org/10.5223/pghn.2022.25.6.461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679302/
https://www.ncbi.nlm.nih.gov/pubmed/36451693
http://dx.doi.org/10.5223/pghn.2022.25.6.461

Ejemplares similares